Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503508 | 0.99 | MEN1 (0.41) | USP14MEN1KMT2AKDM4EEPHX2 | |
| SCHEMBL10051929 | 0.93 | USP14 (0.39) | USP14MEN1KMT2AKDM4EFFAR1 | |
| SCHEMBL503883 | 0.93 | EPHX2 (0.41) | USP14MEN1KMT2AKDM4EEPHX2 | |
| SCHEMBL504103 | 0.92 | EPHX2 (0.41) | USP14MEN1KMT2AKDM4EEPHX2 | |
| SCHEMBL503483 | 0.84 | IDH1 (0.36) | USP14MEN1KMT2AKDM4E | |
| SCHEMBL10051928 | 0.80 | KDM4E (0.57) | USP14MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL504228 | 0.79 | EPHX2 (0.39) | USP14KDM4EEPHX2ALDH1A1 | |
| SCHEMBL333485 | 0.79 | USP14 (0.56) | USP14MEN1KMT2AFFAR1ALDH1A1 | |
| SCHEMBL334162 | 0.79 | USP14 (0.52) | USP14MEN1KMT2AKDM4ETHRB | |
| SCHEMBL10076916 | 0.78 | PPARG (0.47) | USP14MEN1KMT2AKDM4EEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | USP14 2929/4885MEN1 2934/4885KMT2A 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.